Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Abnormal brain protein targeted in Parkinson's study

Researchers have identified a new brain protein involved in the development of Parkinson's...

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...

Newborns have elevated levels of an Alzheimer's biomarker

What do the brains of newborns and patients with Alzheimer's disease have in common? Both...

Content from other channels on our network

Wage theft: law changes, compliance and prevention in health care

Deepfakes mimicking health professionals pose real risk

Diagnostic reference levels for mammography now a step closer

Renewal fee rebate for parental and other leave now in effect

SA reaches state-first allied health enterprise agreement

Returnable deli containers on trial in two NZ supermarkets

Olivo and Brunetti Oro: cool partnership for fine food

Maxum Foods appoints its first CEO

Suntory Oceania’s $3bn beverage business launched in Qld

Heat and Control showcases sustainable food processing solutions

Wind energy study to protect wildlife from collisions

Battery life and EV cybersecurity projects receive funding

Queesland to become HVAC&R innovation hotspot

Inverell upgrades 30-year-old aeration system

Agricultural waste to create sustainable textiles